CLSD
Price
$0.38
Change
-$0.03 (-7.32%)
Updated
Aug 7 closing price
Capitalization
32.04M
10 days until earnings call
NEVPF
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Jan 23 closing price
Capitalization
45.13M
Interact to see
Advertisement

CLSD vs NEVPF

Header iconCLSD vs NEVPF Comparison
Open Charts CLSD vs NEVPFBanner chart's image
Clearside Biomedical
Price$0.38
Change-$0.03 (-7.32%)
Volume$611.05K
Capitalization32.04M
Abliva AB
Price$0.03
Change-$0.00 (-0.00%)
Volume$58.9K
Capitalization45.13M
CLSD vs NEVPF Comparison Chart in %
Loading...
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLSD vs. NEVPF commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLSD is a Hold and NEVPF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (CLSD: $0.38 vs. NEVPF: $0.03)
Brand notoriety: CLSD and NEVPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLSD: 10% vs. NEVPF: 100%
Market capitalization -- CLSD: $32.04M vs. NEVPF: $45.13M
CLSD [@Biotechnology] is valued at $32.04M. NEVPF’s [@Biotechnology] market capitalization is $45.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLSD’s FA Score shows that 0 FA rating(s) are green whileNEVPF’s FA Score has 0 green FA rating(s).

  • CLSD’s FA Score: 0 green, 5 red.
  • NEVPF’s FA Score: 0 green, 5 red.
According to our system of comparison, NEVPF is a better buy in the long-term than CLSD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLSD’s TA Score shows that 5 TA indicator(s) are bullish.

  • CLSD’s TA Score: 5 bullish, 5 bearish.

Price Growth

CLSD (@Biotechnology) experienced а -8.07% price change this week, while NEVPF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

CLSD is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NEVPF($45.1M) has a higher market cap than CLSD($32M). NEVPF YTD gains are higher at: -22.222 vs. CLSD (-59.684). CLSD has higher annual earnings (EBITDA): -19.77M vs. NEVPF (-87.99M). NEVPF has more cash in the bank: 32.7M vs. CLSD (13.6M). CLSD has higher revenues than NEVPF: CLSD (3.76M) vs NEVPF (0).
CLSDNEVPFCLSD / NEVPF
Capitalization32M45.1M71%
EBITDA-19.77M-87.99M22%
Gain YTD-59.684-22.222269%
P/E RatioN/AN/A-
Revenue3.76M0-
Total Cash13.6M32.7M42%
Total Debt619KN/A-
FUNDAMENTALS RATINGS
CLSD vs NEVPF: Fundamental Ratings
CLSD
NEVPF
OUTLOOK RATING
1..100
9538
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
90
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
9741
P/E GROWTH RATING
1..100
81100
SEASONALITY SCORE
1..100
5018

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLSD's Valuation (89) in the Pharmaceuticals Major industry is in the same range as NEVPF (90) in the null industry. This means that CLSD’s stock grew similarly to NEVPF’s over the last 12 months.

CLSD's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as NEVPF (100) in the null industry. This means that CLSD’s stock grew similarly to NEVPF’s over the last 12 months.

NEVPF's SMR Rating (99) in the null industry is in the same range as CLSD (100) in the Pharmaceuticals Major industry. This means that NEVPF’s stock grew similarly to CLSD’s over the last 12 months.

NEVPF's Price Growth Rating (41) in the null industry is somewhat better than the same rating for CLSD (97) in the Pharmaceuticals Major industry. This means that NEVPF’s stock grew somewhat faster than CLSD’s over the last 12 months.

CLSD's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as NEVPF (100) in the null industry. This means that CLSD’s stock grew similarly to NEVPF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLSDNEVPF
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
N/A
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
15%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
15%
Advances
ODDS (%)
Bullish Trend 17 days ago
82%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
N/A
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GALT3.820.05
+1.33%
Galectin Therapeutics
KFFB3.120.04
+1.20%
Kentucky First Federal Bancorp
CTS38.570.16
+0.42%
CTS Corp
FELE93.33-0.51
-0.54%
Franklin Electric Co
INFY16.02-0.18
-1.11%
Infosys Limited

CLSD and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLSD has been loosely correlated with ABVX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CLSD jumps, then ABVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLSD
1D Price
Change %
CLSD100%
-7.11%
ABVX - CLSD
52%
Loosely correlated
-1.26%
NEVPF - CLSD
35%
Loosely correlated
N/A
ANEB - CLSD
31%
Poorly correlated
-11.11%
IMNN - CLSD
30%
Poorly correlated
+1.21%
BOLT - CLSD
29%
Poorly correlated
+0.53%
More

NEVPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, NEVPF has been loosely correlated with REPL. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if NEVPF jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NEVPF
1D Price
Change %
NEVPF100%
N/A
REPL - NEVPF
64%
Loosely correlated
-0.36%
PMN - NEVPF
49%
Loosely correlated
-6.76%
TNXP - NEVPF
41%
Loosely correlated
-1.64%
CLSD - NEVPF
35%
Loosely correlated
-7.11%
CLLS - NEVPF
32%
Poorly correlated
-1.48%
More